Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Uterine Cervical Neoplasms 1Solid Neoplasms 1SCLC 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Metastatic Solid Tumors 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Injections 2Infusions, Intravenous 2tislelizumab 1sacituzumab govitecan 1bintrafusp alfa protein, human 1avelumab 1Platinum 1Gemcitabine 1DOXO-EMCH 1Cetuximab 1(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Solid Tumors × Platinum × Clear all
NCT07272590 2025-12-09

Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
290 enrolled
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡